Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Target

Leukemic cells

1 abstract

Abstract
Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.
Org: Jazz Pharmaceuticals, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Dana-Farber Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, H. Lee Moffitt Cancer Center and Research Institute,